Reviewed by Michael Gill, B. Sc.
25 Lynparza Clinical Trials Near Me
Top Cities for Lynparza Clinical Trials
Image of Boston in Massachusetts.
72Active Trials
Dana-Farber Cancer InstituteTop Active Site
Image of New York in New York.
New York
54Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Lynparza Clinical Trials by Phase of Trial
Phase < 1 Lynparza Clinical Trials
5Active Lynparza Clinical Trials
5Number of Unique Treatments
4Number of Active Locations
Radiation therapyOlaparibCobimetinibDasatinibLynparza
Most Recent Lynparza Clinical Trials
Clinical Trial
Began Recruiting Date

What Are Lynparza Clinical Trials?

Lynparza is a form of cancer medication that helps to stop the growth and spread of certain cancers within the body. Lynparza is most known for having therapeutic effects on ovarian cancer, fallopian tube cancer, and peritoneal cancer in women, as a result of an abnormal inherited gene. Lynparza is often administered after cancer has gone into remission, but has resurfaced after a short period. Lynparza is also used for HER2-negative breast cancer, to help stop the spread of this type of cancer to other body parts before effective remedies are administered, such as chemotherapy and hormonal therapy.

Why Is Lynparza Being Studied In Clinical Trials?

Lynparza is the brand name of the substance Olaparib, which is currently being studied solely for its implications on modern cancer treatments. At this time, Olaparib's efficacy is being compared to other known substances purported to have similar effects, such as enzalutamide or abiraterone acetate. Olaparib does not seem to eliminate cancer at the root of the problem but is more useful in the cessation of the spread of cancer within the body.

How Does Lynparza Treatment Work?

Lynparza comes in the form of an ingested tablet that is swallowed by the patient, which contains the olaparib substance. Olaparib is a biological drug that is made from parts of living organisms. Olaparib operates only under the brand name Lynparza as it is not currently available in a biosimilar form, meaning that off-brand or generic (non-biological) substances cannot be substituted for it at this current time.

The treatment is often prescribed in conjunction with other known methods, such as chemotherapy or hormonal treatment. Lynaprza is prescribed for metastatic conditions, meaning that it is best used for cases where the issue seems to be spreading. Lynparza treats cancer by blocking the actions of specific proteins that speed up reactions in your body. Blocking these enzymes causes the damage done by cancer cells to be limited to a certain area.

Cancer itself is a condition where your cells are multiplying faster than they can be sustained. Therefore, if they are limited, cancer cells die out on their own.

What Are Some of the Breakthrough Clinical Trials Involving Lynparza?

2013: 25 women with inherited BRCA mutations and advanced ovarian cancer were treated with Olaparib after taking a platinum-based chemotherapy treatment. Of these 295 women, 99 were given a placebo, while the rest were administered Lynparza. Women who were given Lynparza didn't see progression in their cancer for a median of 19.1 months, as compared to 5.5 months on placebo alone.

2014: 302 people were tested with an inherited abnormal BRC mutation and HER2-negative metastatic breast cancer. These patients were previously treated with chemotherapy, or hormonal therapy if they were HR-positive. Lynparza was shown to completely delay the cancer progression by around 6 months, compared to 4.2 months in patients with only chemotherapy or hormonal therapy.

Who Are The Key Opinion Leaders On Lynparza Clinical Trial Research?

Professor Dr. Uwe M Martens of the SLK Kliniken Heilbronn GmbH- Department of Hematology/Oncology/Palliative Care co-authored a well-cited article on Olaparib in August 2018.

Professor Dr. Ulrich Warnke, Head of Pharmacy in Potsdam, co-authored an extremely important paper in 2022 titled "Novel approach of desensitization in an allergic reaction to Olaparib"

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: October 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.